GH release after GHRH plus arginine administration in obese and overweight women with polycystic ovary syndrome
- PMID: 12739737
- DOI: 10.1007/BF03345138
GH release after GHRH plus arginine administration in obese and overweight women with polycystic ovary syndrome
Abstract
Few and unclear data are available in the literature about the relationship between impairment of GH/IGF-I axis and polycystic ovary syndrome (PCOS). This study was aimed to evaluate the basal GH and IGF- levels, and GH release after challenge test in obese and overweight women with PCOS. Thirty patients with PCOS and other 30 healthy women matched for age, body mass index (BMI) and waist-hip ratio (WHR) were studied. Serum follicle-stimulating hormone (FSH), LH, PRL, E2, P, 17OH-progesterone (17OH-P), total T, delta4, DHEA-S, SHBG, GH and IGF-I levels were evaluated in each subject. A GHRH plus arginine challenge test was performed in all subjects. After provocative test, in PCOS and control women the GH levels were significantly (p<0.05) higher in comparison to basal values from 30 min to 120 min. At the same times, a significant (p<0.05) difference was observed between women with PCOS in comparison to healthy women. The mean peak value of GH resulted significantly (p<0.05) lower in PCOS women in comparison to healthy women. The total GH response (area under curve, AUC) to GHRH plus arginine test resulted significantly (p<0.05) lower in PCOS than in healthy women. These findings were statistically significant (p<0.05) also considering the distinction in obese and overweight women. The AUC for GH secretion was significantly lower (p<0.05) in obese in comparison to overweight subjects in the control group, whereas no significant difference was detected between obese and overweight women in the PCOS group. In conclusion, in PCOS women there is a BMI-independent alteration of the GH levels. Further investigations will be necessary to establish the real cause of these data.
Similar articles
-
Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.Fertil Steril. 2008 Apr;89(4):899-906. doi: 10.1016/j.fertnstert.2007.04.043. Epub 2007 Nov 5. Fertil Steril. 2008. PMID: 17980364 Clinical Trial.
-
Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.J Clin Endocrinol Metab. 1996 Aug;81(8):2854-64. doi: 10.1210/jcem.81.8.8768842. J Clin Endocrinol Metab. 1996. PMID: 8768842
-
Metastin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome.Eur J Obstet Gynecol Reprod Biol. 2014 Sep;180:56-60. doi: 10.1016/j.ejogrb.2014.06.004. Epub 2014 Jun 13. Eur J Obstet Gynecol Reprod Biol. 2014. PMID: 25020276
-
Reproductive hormone characteristics of obese Chinese patients with polycystic ovarian syndrome: a meta-analysis.Gynecol Endocrinol. 2025 Dec;41(1):2497854. doi: 10.1080/09513590.2025.2497854. Epub 2025 Apr 27. Gynecol Endocrinol. 2025. PMID: 40287875 Review.
-
Hormonal changes in PCOS.J Endocrinol. 2024 Feb 15;261(1):e230342. doi: 10.1530/JOE-23-0342. Print 2024 Apr 1. J Endocrinol. 2024. PMID: 38285626 Review.
Cited by
-
Effects of ghrelin administration on endocrine and metabolic parameters in obese women with polycystic ovary syndrome.J Endocrinol Invest. 2007 Dec;30(11):948-56. doi: 10.1007/BF03349243. J Endocrinol Invest. 2007. PMID: 18250617 Clinical Trial.
-
Growth hormone secretion in primary and secondary hyperparathyroidism.J Endocrinol Invest. 2005 Feb;28(2):113-6. doi: 10.1007/BF03345352. J Endocrinol Invest. 2005. PMID: 15887855
-
Sitagliptin Decreases Visceral Fat and Blood Glucose in Women With Polycystic Ovarian Syndrome.J Clin Endocrinol Metab. 2020 Jan 1;105(1):136-51. doi: 10.1210/clinem/dgz028. J Clin Endocrinol Metab. 2020. PMID: 31529097 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous